ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01186861
Recruitment Status : Completed
First Posted : August 23, 2010
Last Update Posted : April 29, 2015
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2013
  Actual Study Completion Date : March 2015
  Certification/Extension First Submitted : June 19, 2014